Genomic classification of cutaneous melanoma

R Akbani, KC Akdemir, B áArman Aksoy, M Albert… - Cell, 2015 - cell.com
We describe the landscape of genomic alterations in cutaneous melanomas through DNA,
RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 …

Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

ML Berres, M Merad, CE Allen - British journal of haematology, 2015 - Wiley Online Library
Langerhans cell histiocytosis (LCH), the most common histiocytic disorder, is characterized
by the accumulation of CD 1A+/CD 207+ mononuclear phagocytes within granulomatous …

Non-genomic and immune evolution of melanoma acquiring MAPKi resistance

W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong… - Cell, 2015 - cell.com
Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling

E Hirata, MR Girotti, A Viros, S Hooper… - Cancer cell, 2015 - cell.com
Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor
reveals how the tumor microenvironment affects response to BRAF inhibition by PLX4720 …

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

G Moriceau, W Hugo, A Hong, H Shi, X Kong… - Cancer cell, 2015 - cell.com
Combined BRAF-and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy
but is still beset by acquired resistance. We show that melanomas acquire resistance to …

Targeting ERK beyond the boundaries of the kinase active site in melanoma

RM Sammons, R Ghose, KY Tsai… - Molecular …, 2019 - Wiley Online Library
Abstract Extracellular signal‐regulated kinase 1/2 (ERK1/2) constitute a point of
convergence for complex signaling events that regulate essential cellular processes …

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination

JZ Sanborn, J Chung, E Purdom… - Proceedings of the …, 2015 - National Acad Sciences
Melanoma is difficult to treat once it becomes metastatic. However, the precise ancestral
relationship between primary tumors and their metastases is not well understood. We …

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

ME Cabanillas, R Dadu, P Iyer, KB Wanland… - Thyroid, 2020 - liebertpub.com
Background: The BRAFV600E mutation is the most common driver mutation in papillary
thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered …

Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence

KR Singleton, L Crawford, E Tsui, HE Manchester… - Cell reports, 2017 - cell.com
Diverse pathways drive resistance to BRAF/MEK inhibitors in BRAF-mutant melanoma,
suggesting that durable control of resistance will be a challenge. By combining statistical …

[HTML][HTML] ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition

B Wang, EB Krall, AJ Aguirre, M Kim, HR Widlund… - Cell reports, 2017 - cell.com
Intrinsic resistance and RTK-RAS-MAPK pathway reactivation has limited the effectiveness
of MEK and RAF inhibitors (MAPKi) in RAS-and RAF-mutant cancers. To identify genes that …